Navigation Links
Genetic fingerprints identify brain tumors' origins

Genetic fingerprints that reveal where a brain cell came from remain distinct even after the cell becomes a brain tumor, an international coalition of scientists will report in the February 1 issue of Cancer Research.

The finding adds a new layer of complexity to the quest to understand the causes of childhood brain cancers, according to senior author David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology at Washington University School of Medicine in St. Louis and co-director of the neuro-oncology program at the Siteman Cancer Center.

"Our findings suggest that brain tumors arising in different regions may be genetically distinct as a consequence of their unique cellular origins," Gutmann says. "This is yet another factor we need to consider when trying to understand how pediatric brain tumors form."

Researchers use information about tumor origins to develop new tests and treatments for the tumors. Brain tumors are the leading cause of cancer-related death in children, and the most common childhood brain tumor is the pilocytic astrocytoma (PA). Approximately 15 percent of all PAs are linked to neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors and is a primary focus of Gutmann's research. However, the genetic basis for the majority of PAs is unexplained.

In the new study, Gutmann led six laboratories in the most detailed genetic analysis of PAs to date.

"We were hoping to identify genes that contribute to the formation of these tumors and find indicators that might help us predict which tumors will be relatively well-behaved and which will be more aggressive," Gutmann says. Previous studies have failed to produce any solid leads on the genetic alterations that predispose children to PAs.

"It should be recognized that the genetic alterations in this tumor may be very subtle," Gutmann notes. "When we looked at gene activity levels in the tumors as a f unction of brain location, though, a very interesting pattern began to emerge."

Cells in different parts of the brain carry the same genes, but they also contain factors that modify the use of those genes, suppressing some genes and activating others to allow the cells to take on specialized characteristics as the brain matures. These changes in gene activity levels are called changes in gene expression.

The researchers found that tumors arising in different regions of the brain retain distinct patterns of gene expression. These patterns provided genetic fingerprints or bar codes for the location of PAs, as well as for another glial cell tumor called an ependymoma. In addition, scientists also detected these distinct patterns of expression in normal glia and stem cells from these brain locations, suggesting that genetic fingerprints can be used to identify the potential origins of brain tumors.

"There's been a movement in recent years to link normal brain development to pediatric neuro-oncology, and these findings affirm that as a necessary approach," Gutmann says. "We won't fully understand the causes of pediatric brain tumors until we consider them in the context of factors that shape the development and specialization of different brain regions."


'"/>

Source:Washington University School of Medicine


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Genetically modified natural killer immune cells attack, kill leukemia cells
3. Ants Genetic Engineering Leads To Species Interdependency
4. Genetic Variation Visualization - From EMBL
5. Genetically modified rice in China benefits farmers health, study finds
6. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
7. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
8. Genetic defects give the immune system the green light to attack the pancreas
9. Maine Researchers Find Exceptions to Old Rules of Genetic Inheritance
10. Genetic therapy reverses nervous system damage in animal model of inherited human disease
11. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... 2016 Research and Markets has announced the ... report to their offering. ... The ... 2021 from USD 6.21 Billion in 2016, growing at a CAGR ... the bioinformatics market is driven by the growing demand for nucleic ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... Equicare Health Inc ., the leading supplier of comprehensive ... the top 100 companies in the 2016 Global Digital ... top digital health companies across the globe.   ... continually upgrading our product with the ongoing digital shift ... Len Grenier , CEO of Equicare Health, "It,s ...
(Date:11/30/2016)... Part of 5m$ Investment in Integrated Drug Discovery ... , ... announced that it had successfully completed the expansion of their ... the Screening Collection to over 400,000. The new compounds were ... company. This expansion, complemented by new robotics and compound management ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the development of a new orally administered treatment for Alzheimer’s disease (AD), today ... of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s ...
Breaking Biology Technology: